Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
businesswire.com
news
2022-06-03 00:00:00

June 03, 2022 08:00 AM Eastern Daylight Time HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the 'Company' or 'Pulse Biosciences'), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today preliminary results of its rights offering, which expired at 5:00 p.m., Eastern Time, on May 26, 2022 (the 'Expiration Date').

In accordance with the pricing structure described in the prospectus supplement relating to the rights offering, the final subscription price for the units offered (the 'Units') is $2.
